Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma

Prostate

Volumn 76, Issue 5, 2016, Pages 479-490

  Kibel, Adam S ^a   Ahn, Jiyoung ^b   Isikbay, Masis ^a   Klim, Aleksandra ^c   Wu, William S ^c   Hayes, Richard B ^b   Isaacs, William B ^d   Daw, E Warwick ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

cancer susceptibility; cell cycle; metastatic disease; prostate carcinoma; risk assessment

Indexed keywords

CYCLIN C; CYCLIN D3; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 6; CYCLIN G1; PROTEIN MDM2; S PHASE KINASE ASSOCIATED PROTEIN 2; SMAD3 PROTEIN; TELOMERIC REPEAT BINDING FACTOR 2; CELL CYCLE PROTEIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CCNC GENE; CCND3 GENE; CCNG1 GENE; CCNT2 GENE; CDK2 GENE; CDK5 GENE; CDK6 GENE; CONTROLLED STUDY; EUROPEAN AMERICAN; GENE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RB1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SKP2 GENE; SMAD3 GENE; TERF2 GENE; WEE1 GENE; YWHAB GENE; YWHAH GENE; CELL CYCLE CHECKPOINT; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; VERY ELDERLY;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 84958778686     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23139     Document Type: Article

References (84)

1. Siegel RL, Miller KD, Jemal A,. Cancer statistics, 2015. CA Cancer J Clin 2015; 65 (1): 5-29.
2. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H,. Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst 2009; 101 (6): 374-383.
3. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ,. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94 (13): 981-990.
4. Auvinen A, Moss S, Tammela TL, Taari K, Roobol M, Schroder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J,. Absolute effect of prostate cancer screening: Balance of benefits and harms by center within the European randomized study of prostate cancer screening. Clin Cancer Res 2015.
5. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr., Wallace ME, Kantoff PW, Carroll PR,. Active surveillance for early-stage prostate cancer: Review of the current literature. Cancer 2008; 112 (8): 1650-1659.
6. Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG, de Bono JS,. Prostate cancer. Lancet 2015. [epub ahead of print].
7. Cooper BT, Sanfilippo NJ,. Concurrent chemoradiation for high-risk prostate cancer. World J Clin Oncol 2015; 6 (4): 35-42.
8. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fossa SD, Scandinavian Prostate Cancer Group S, Swedish Association for Urological O. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised phase III trial. Lancet 2009; 373 (9660): 301-308.
9. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W, investigators NCPMUP,. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. Lancet 2011; 378 (9809): 2104-2111.
10. Cookson MS, Lowrance WT, Murad MH, Kibel AS, American Urological A. Castration-resistant prostate cancer: AUA guideline amendment. J Urol 2015; 193 (2): 491-499.
11. Black PC,. Radical prostatectomy trumps watchful waiting in early prostate cancer. Commentary on: Radical prostatectomy or watchful waiting in early prostate cancer. Urology 2014; 84 (2): 253-254.
12. Hunter K, Welch DR, Liu ET,. Genetic background is an important determinant of metastatic potential. Nat Genet 2003; 34 (1): 23-24; author reply 25.
13. Goldberger NE, Hunter KW,. A systems biology approach to defining metastatic biomarkers and signaling pathways. Wiley Interdiscip Rev Syst Biol Med 2009; 1 (1): 89-96.
14. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, yrer J, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Roder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE, Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L, Cybulski C, Wokolorczyk D, Kluzniak W, Park J, Sellers T, Lin HY, Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C, Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM, Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM, Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S, Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA, Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL, Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C, Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D, Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ, Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G, Breast Prostate Cancer Cohort C, Consortium P, Consortium C, Consortium G-OE, Cook MB, Nakagawa H, Wiklund F, Kraft P, Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA,. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 2014; 46 (10): 1103-1109.
15. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Roder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC, Initiative CO-CRUG-E, Australian Prostate Cancer B, Oncology UKGPCSCBAoUSSo, Collaborators UKPS, Consortium P, Kote-Jarai Z, Easton DF,. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45 (4): 385-391, 391e381-382.
16. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Balter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Gronberg H,. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358 (9): 910-919.
17. Beebe-Dimmer JL, Levin AM, Ray AM, Zuhlke KA, Machiela MJ, Halstead-Nussloch BA, Johnson GR, Cooney KA, Douglas JA,. Chromosome 8q24 markers: Risk of early-onset and familial prostate cancer. Int J Cancer 2008; 122 (12): 2876-2879.
18. Cussenot O, Azzouzi AR, Bantsimba-Malanda G, Gaffory C, Mangin P, Cormier L, Fournier G, Valeri A, Jouffe L, Roupret M, Fromont G, Sibony M, Comperat E, Cancel-Tassin G,. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer. Clin Cancer Res 2008; 14 (17): 5635-5639.
19. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley KE, Balter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W, Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs WB, Gronberg H, Xu J, Carpten JD,. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99 (24): 1836-1844.
20. Mononen N, Seppala EH, Duggal P, Autio V, Ikonen T, Ellonen P, Saharinen J, Saarela J, Vihinen M, Tammela TL, Kallioniemi O, Bailey-Wilson JE, Schleutker J,. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 2006; 66 (2): 743-747.
21. Ross PL, Cheng I, Liu X, Cicek MS, Carroll PR, Casey G, Witte JS,. Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer. BMC Cancer 2009; 9: 69.
22. Hayes VM, Severi G, Eggleton SA, Padilla EJ, Southey MC, Sutherland RL, Hopper JL, Giles GG,. The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol Biomarkers Prev 2005; 14 (4): 993-996.
23. Sun J, Zheng SL, Wiklund F, Isaacs SD, Li G, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC, Turner AR, Stattin P, Liu W, Kim JW, Duggan D, Carpten J, Isaacs W, Gronberg H, Xu J, Chang BL,. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res 2009; 69 (1): 10-15.
24. Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, FitzGerald LM, Henderson BE, Schumacher FR, Haiman CA, Sipeky C, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubinski J, Kluzniak W, Cannon-Albright L, Brenner H, Herrmann V, Holleczek B, Park JY, Sellers TA, Lim HY, Slavov C, Kaneva RP, Mitev VI, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, consortium P, Batra J, Clements JA, Australian Prostate Cancer B, Albanes D, Andriole GL, Berndt SI, Chanock S, Gapstur SM, Giovannucci EL, Hunter DJ, Kraft P, Le Marchand L, Ma J, Mondul AM, Penney KL, Stampfer MJ, Stevens VL, Weinstein SJ, Trichopoulou A, Bueno-de-Mesquita BH, Tjonneland A, Cox DG, consortium BPC, Maehle L, Schleutker J, Lindstrom S, Wiklund F,. Genome-wide association study of prostate cancer-specific survival. Cancer Epidemiol Biomarkers Prev 2015; 24 (11): 1796-1800.
25. Kibel AS, Isaacs WB,. G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology 2000; 55 (3): 316-322.
26. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM,. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39 (1): 41-51.
27. Elledge SJ,. Cell cycle checkpoints: Preventing an identity crisis. Science 1996; 274 (5293): 1664-1672.
28. Dukelow T, Kishan D, Khasraw M, Murphy CG,. CDK4/6 inhibitors in breast cancer. Anti-Cancer Drugs 2015; 26 (8): 797-806.
29. Nichols M,. New directions for drug-resistant breast cancer: The CDK4/6 inhibitors. Future Med Chem 2015; 7 (12): 1473-1481.
30. Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H, Hara M, Saito I,. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 1998; 16 (13): 1701-1712.
31. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J,. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995; 11 (5): 1005-1011.
32. Pim D, Banks L,. P53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004; 108 (2): 196-199.
33. Belanger H, Beaulieu P, Moreau C, Labuda D, Hudson TJ, Sinnett D,. Functional promoter SNPs in cell cycle checkpoint genes. Hum Mol Genet 2005; 14 (18): 2641-2648.
34. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ,. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119 (5): 591-602.
35. Liu Y, Kwiatkowski DJ,. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. Mol Cancer Ther 2015; 14 (1): 174-182.
36. Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C,. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003; 9 (13): 4860-4864.
37. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K,. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 2000; 10 (4): 307-311.
38. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, Wang Y, Lin D,. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006; 27 (1): 110-117.
39. Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, Okugi H, Koike H, Ono Y, Ito K, Kurokawa K, Yamanaka H,. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003; 10 (4): 430-435.
40. Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM,. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001; 49 (4): 263-266.
41. Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H, Tsuchiya N, Sato K, Ohyama C, Nakamura A, Ogawa O, Kato T,. Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 2003; 103 (1): 116-120.
42. Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, Walsh PC, Meyers DA, Isaacs WB, Xu J,. A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 2004; 64 (6): 1997-1999.
43. Bansal A, Soni A, Rao P, Singh LC, Mishra AK, Mohanty NK, Saxena S,. Implication of DNA repair genes in prostate tumourigenesis in Indian males. Indian J Med Res 2012; 136 (4): 622-632.
44. Babaei F, Ahmadi SA, Abiri R, Rezaei F, Naseri M, Mahmoudi M, Nategh R, Mokhtari Azad T,. The TP53 codon 72 polymorphism and risk of sporadic prostate cancer among Iranian patients. Iran J Public Health 2014; 43 (4): 453-459.
45. Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, Guo C, Catalona WJ, Picus J, Goodfellow PJ,. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 2003; 63 (9): 2033-2036.
46. Kibel AS, Jin CH, Klim A, Luly J, K AR, Wu WS, Suarez BK,. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate 2008; 68 (11): 1179-1186.
47. Yang J, Gao W, Song NH, Wang W, Zhang JX, Lu P, Hua LX, Gu M,. The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: A meta-analysis. Asian J Androl 2012; 14 (5): 726-731.
48. Xue L, Han X, Liu R, Wang Z, Li H, Chen Q, Zhang P, Wang Z, Chong T,. MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer. Oncotarget 2015.
49. Lubahn J, Berndt SI, Jin CH, Klim A, Luly J, Wu WS, Isaacs S, Wiley K, Isaacs WB, Suarez BK, Hayes RB, Kibel AS,. Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate 2010; 70 (6): 646-653.
50. KEGG. http://www.genome.jp/kegg/pathway.html 2010.
51. NCBI dbSNP database. Volume 2009: http://www.ncbi.nlm.nih.gov/SNP/; 2009.
52. Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, Gunderson KL, Hansen M, Steemers F, Butler SL, Deloukas P, Galver L, Hunt S, McBride C, Bibikova M, Rubano T, Chen J, Wickham E, Doucet D, Chang W, Campbell D, Zhang B, Kruglyak S, Bentley D, Haas J, Rigault P, Zhou L, Stuelpnagel J, Chee MS,. Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol 2003; 68: 69-78.
53. Marsh S, King CR, Garsa AA, McLeod HL,. Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol 2005; 311: 97-114.
54. Akoulitchev S, Chuikov S, Reinberg D,. TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature 2000; 407 (6800): 102-106.
55. Ren S, Rollins BJ,. Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 2004; 117 (2): 239-251.
56. Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T,. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003; 424 (6945): 223-228.
57. Saxena UH, Powell CM, Fecko JK, Cacioppo R, Chou HS, Cooper GM, Hansen U,. Phosphorylation by cyclin C/cyclin-dependent kinase 2 following mitogenic stimulation of murine fibroblasts inhibits transcriptional activity of LSF during G1 progression. Mol Cell Biol 2009; 29 (9): 2335-2345.
58. Li H, Lahti JM, Valentine M, Saito M, Reed SI, Look AT, Kidd VJ,. Molecular cloning and chromosomal localization of the human cyclin C (CCNC) and cyclin E (CCNE) genes: Deletion of the CCNC gene in human tumors. Genomics 1996; 32 (2): 253-259.
59. Polly P, Danielsson C, Schrader M, Carlberg C,. Cyclin C is a primary 1alpha,25-dihydroxyvitamin D(3) responding gene. J Cell Biochem 2000; 77 (1): 75-81.
60. Hellmich MR, Pant HC, Wada E, Battey JF,. Neuronal cdc2-like kinase: A cdc2-related protein kinase with predominantly neuronal expression. Proc Natl Acad Sci USA 1992; 89 (22): 10867-10871.
61. Liu SL, Wang C, Jiang T, Tan L, Xing A, Yu JT,. The Role of Cdk5 in Alzheimer's Disease. Mol Neurobiol 2015. [epub ahead of print].
62. Klinman E, Holzbaur EL,. Stress-Induced CDK5 Activation Disrupts Axonal Transport via Lis1/Ndel1/Dynein. Cell Rep 2015; 12 (3): 462-473.
63. Sheng Y, Zhang L, Su SC, Tsai LH, Julius Zhu J,. Cdk5 is a new rapid synaptic homeostasis regulator capable of initiating the early alzheimer-like pathology. Cereb Cortex 2015. [epub ahead of print].
64. Hsu FN, Chen MC, Chiang MC, Lin E, Lee YT, Huang PH, Lee GS, Lin H,. Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J Biol Chem 2011; 286 (38): 33141-33149.
65. Strock CJ, Park JI, Nakakura EK, Bova GS, Isaacs JT, Ball DW, Nelkin BD,. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 2006; 66 (15): 7509-7515.
66. Lindqvist J, Imanishi SY, Torvaldson E, Malinen M, Remes M, Orn F, Palvimo JJ, Eriksson JE,. Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells. Mol Biol Cell 2015; 26 (11): 1971-1984.
67. Hsu FN, Chen MC, Lin KC, Peng YT, Li PC, Lin E, Chiang MC, Hsieh JT, Lin H,. Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser(7)(2)(7) on STAT3 in prostate cancer cells. Am J Physiol Endocrinol Metab 2013; 305 (8): E975-E986.
68. Venter JC., SIFT. Volume 2015; 2015.
69. Ohtsuka T, Jensen MR, Kim HG, Kim KT, Lee SW,. The negative role of cyclin G in ATM-dependent p53 activation. Oncogene 2004; 23 (31): 5405-5408.
70. Kimura SH, Tsuruga H, Yabuta N, Endo Y, Nojima H,. Structure, expression, and chromosomal localization of human GAK. Genomics 1997; 44 (2): 179-187.
71. Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, Rennie PS,. Cyclin G-associated kinase: A novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. Int J Cancer 2006; 118 (5): 1108-1119.
72. Meek DW,. Regulation of the p53 response and its relationship to cancer. Biochem J 2015; 469 (3): 325-346.
73. Bond GL, Hu W, Levine A,. A single nucleotide polymorphism in the MDM2 gene: From a molecular and cellular explanation to clinical effect. Cancer Res 2005; 65 (13): 5481-5484.
74. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D,. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005; 65 (20): 9582-9587.
75. Zhang L, Zhu Z, Wu H, Wang K,. Association between SNP309 and del1518 polymorphism in MDM2 homologue and esophageal squamous cell carcinoma risk in Chinese population of Shandong province. Ann Clin Lab Sci 2015; 45 (4): 433-437.
76. Lv J, Zhu B, Zhang L, Xie Q, Zhuo W,. MDM2 SNP309 variation confers the susceptibility to hepatocellular cancer: A meta-analysis based on 4271 subjects. Int J Clin Exp Med 2015; 8 (4): 5822-5830.
77. Qin J, Cong X, Jin J, Chu Z, Gu X, Cai Y,. Association between MDM2 SNP309 and skin cancer: A meta-analysis of case-control studies. J Dermatol Sci 2015; 79 (2): 171-173.
78. He X, Chen P, Yang K, Liu B, Zhang Y, Wang F, Guo Z, Liu X, Lou J, Chen H,. Association of MDM2 polymorphism with risk and prognosis of leukemia: A meta-analysis. Acta Haematol 2015; 133 (4): 365-371.
79. Mandal RK, Mittal RD,. Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population ? Urol Oncol 2012; 30 (5): 555-561.
80. Huang SP, Wu WJ, Chang WS, Wu MT, Chen YY, Chen YJ, Yu CC, Wu TT, Lee YH, Huang JK, Huang CH,. P53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13 (12): 2217-2224.
81. Sivonova MK, Vilckova M, Jurecekova J, Hatok J, Dobrota D, Dusenka R, Kliment J,. The role of p21 3'UTR gene polymorphism in the risk of prostate cancer: A pilot study. Mol Med Rep 2013; 7 (3): 986-990.
82. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L,. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393 (6682): 229-234.
83. Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, Wong J, Knudsen KE,. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci USA 2006; 103 (7): 2190-2195.
84. Koike H, Suzuki K, Satoh T, Ohtake N, Takei T, Nakata S, Yamanaka H,. Cyclin D1 gene polymorphism and familial prostate cancer: The AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. Anticancer Res 2003; 23 (6D): 4947-4951.